ePT--the Electronic Newsletter of Pharmaceutical Technology
Aegis Therapeutics (San Diego, CA) has launched a new formulation technology to increase the stability of proteins and peptides.
Aegis Therapeutics (San Diego, CA, www.aegisthera.com) has launched a new formulation technology to increase the stability of proteins and peptides.
Edward T. Maggio, PhD, CEO of Aegis Therapeutics, told Pharmaceutical Technology that the company’s “ProTek” nontoxic, inert excipients can be added to a protein or peptide solution during purification and concentration to reduce or eliminate aggregation, which could occur during manufacturing processes when peptides and proteins are manipulated at high concentrations.
“Proteins and peptides like to aggregate,” he says. “In some cases, it’s not a problem at all, but in other cases it gives rise to immunogenicity or loss of activity. As they aggregate, their absorption into systemic circulation decreases.” With certain formulations, unwanted immunogenicity could cause serious adverse effects or even death.
Aggregation also could occur during extended storage, which causes challenges for cold-chain management of products such as insulin injections. “There are no room-temperature insulins right now. There are issues with denaturization and loss of activity,” notes Maggio. “We think insulin could be an exciting application for ProTek.” The company also has studied the possibility of using its technology to stabilize human growth hormones as well as a nasal-administered anti-HIV peptide that reduces viral levels and flushes active virals from monocytes.
The technology is suitable for aqueous or lyophilized dosage forms that are delivered through injectable, intranasal, pulmonary, oral or other transmucosal routes.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.